950220 — Neoimmunetech Share News
0.000.00%
Last trade - 00:00- KR₩542bn
- KR₩495bn
- $0.07m
Brief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment
Brief: Neoimmunetech Presents Phase 1 Study Data At Society For Neuro-Oncology Annual Meeting
Brief: Neoimmunetech Receives U.S. FDA Ind Clearance For Phase 1 Study Of NT-I7 For Treatment Of Kaposi Sarcoma In Patients With Or Without HIV Infection
Brief: Neoimmunetech Announces First Patient Dosed In The Pilot Study Of NT-I7 In Progressive Multifocal Leukoencephalopathy
Brief: Neoimmunetech Inc Says First Patient Dosed In Study Evaluating Nt-I7 & Keytruda In Advanced Solid Tumors